WO1998014243A1 - Intracorporeal light treatment of blood - Google Patents
Intracorporeal light treatment of blood Download PDFInfo
- Publication number
- WO1998014243A1 WO1998014243A1 PCT/US1997/014781 US9714781W WO9814243A1 WO 1998014243 A1 WO1998014243 A1 WO 1998014243A1 US 9714781 W US9714781 W US 9714781W WO 9814243 A1 WO9814243 A1 WO 9814243A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- light
- patient
- housing
- photoreactor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
Definitions
- the present invention generally relates to an invention for using light to administer a medical treatment to blood, and more specifically, to apparatus and a method for exposing blood circulating through a patient's body to light, for the purpose of providing a therapeutic benefit.
- Various diseases of the blood can be best treated by a technique that affects only a selected type of organism in the blood to avoid undesired consequences relating to the other functions that blood performs.
- Extracorporeal photochemotherapy or photopheresis is currently a preferred treatment for such diseases.
- heparinized venous blood is treated with a photosensitizing agent such as 8-methoxypsoralen (which may be ingested orally).
- the photosensitizing agent which is preferentially absorbed by abnormal or malignant T-cell lymphocytes that are to be destroyed, is circulated outside the body and exposed to UVA light having a waveband corresponding to an absorption waveband of the psoralen. After being exposed to the light source, the blood is returned to the patient's body.
- the extracorporeal photodynamic therapy (PDT) of blood in this manner is typically done at a hospital or other medical facility and is a relatively time consuming procedure (e.g., up to six hours or possibly more per treatment, repeated on consecutive days, at monthly intervals) that has a substantial impact on the life of the patient undergoing the therapy.
- photochemotherapy of blood is only available at certain medical institutions, it may be necessary for a patient to travel some distance in order to reach a place where the treatment can be obtained.
- apparatus for administering intracorporeal photopheresis to blood flowing in a patient's body to destroy an undesirable component in the blood, where the undesirable component has absorbed a photoreactive agent having a characteristic light absorption waveband.
- the apparatus includes an implantable housing adapted to be transcutaneously placed at a site within a patient's body, being made of a biocompatible material.
- An inlet port and an outlet port are provided in the housing and are adapted to couple to a patient's circulatory system to convey the blood circulated thereby into and out of the housing.
- a light source disposed within the housing emits light having a waveband substantially equal to the absorption waveband of the photoreactive agent.
- a fluid path is disposed within the housing, adjacent to the light source and in fluid communication with the inlet port and outlet port. At least a portion of the fluid path is optically transparent, so that blood circulating through the fluid path is irradiated with the light emitted by the light source to effect the light treatment.
- the fluid path preferably comprises one of several different shaped passages, depending upon the embodiment. Various embodiments thus comprise either a serpentine shaped passage, a helically-coiled passage, a substantially planar coil, or a plurality of parallel passages extending between two headers. In the latter embodiment, one of the two headers is coupled to the inlet port and the other header is coupled to the outlet port.
- One such light source comprises a generally planar array of spaced-apart light emitting devices, which is preferably coupled with another generally planar array of spaced-apart light emitting devices.
- the arrays are disposed at opposite sides of the fluid path, and the light emitting devices are directed so as to emit light toward the fluid path.
- the light emitting devices are preferably mounted on a substantially light reflecting surface.
- the light source comprises a bar that includes a plurality of light emitting devices, which are spaced apart generally along a longitudinal axis of the bar.
- the light source comprises a plurality of optical fibers that are coupled to a light emitting device.
- the power source is integral with the housing.
- the power source may be disposed within ah enclosure comprising a biocompatible material and is thus adapted to be implanted within the patient's body, separate from the housing for the light source.
- the housing may include a tab that is usable for securing the housing at a desired location within the patient's body. For example, sutures can be threaded through a hole in the tab to secure the housing to an adjacent rib or other structure within the patient's body. It is also desirable that the housing have a substantially light reflective inner surface to improve the irradiation of blood flowing therethrough.
- the inlet port and the outlet port preferably comprise vascular graft tubing.
- the vascular graft tubing enables a physician to suture the vascular graft tubing to the ends of a transected blood vessel within the patient's body.
- an inner surface of the fluid path may be coated with a substance, such as heparin, which resists the formation of blood clots.
- Another aspect of the present invention is directed to a method for treating blood flowing in a patient's body to destroy an undesirable component.
- the method includes steps that are generally consistent with the functions described above in connection with the apparatus used for administering intracorporeal photopheresis of blood.
- FIGURE 1 is a perspective view, with portions broken away, showing a section of a helical coil apparatus for treating fluids using PDT;
- FIGURE 2 is a top sectional view of the helical coil apparatus shown in FIGURE 1 ;
- FIGURE 3 is a perspective view of a reactor housing having serpentine tubing and a light source therein;
- FIGURE 4 is a top sectional view of the apparatus shown in FIGURE 3;
- FIGURE 5 is a side sectional view showing the reactor housing with tubing and light source installed therein;
- FIGURE 6 is a side sectional view of the reactor housing showing a molded shape with a plurality of parallel passages extending between an inlet header and an outlet header;
- FIGURE 7 is a side sectional view of a reactor housing showing an LED grid array light source installed therein;
- FIGURE 8 is a cross-sectional view of a substantially planar coil apparatus for treating fluids using PDT
- FIGURE 9 is a side sectional view of the substantially planar coil apparatus shown in FIGURE 8;
- FIGURE 10 is a top perspective view, with portions in relief, showing a serpentine coil apparatus for treating fluids using PDT with a fiber optic mat light source contained therein;
- FIGURE 11 is a side sectional view of the apparatus shown in FIGURE 10; and FIGURE 12 is a perspective view showing a biocompatible reactor housing containing an apparatus for treating fluids using PDT, and showing the apparatus disposed inside a patient's rib cage.
- photopheresis destroys or affects an undesirable component in the blood that has absorbed a photoreactive agent having a characteristic light absorption waveband. It is believed that improved results will be obtained by administering the treatment to a patient's blood for extended periods of time in situ, using various levels of light. Moreover, relatively low intensity light sources are much less likely to cause undesired damage to other components of a patient's blood than the relatively short duration extracorporeal light therapy taught by the prior art. While all but one of the preferred embodiments of the present invention that are described below specifically mention LEDs as the preferred source of light for administering PDT to blood flow, it will be understood that other light sources are equally usable in connection with the present invention. Such alternative light sources include, but are not limited to: laser diodes, vertical cavity surface emitting lasers (VCSELs), light emitting semiconductors, gas discharge sources, light emitting polymers, and filament bulbs.
- VCSELs vertical cavity surface emitting lasers
- FIGURE 1 shows a side sectional view of a housing 100 comprising a cylindrical wall 120 having a top end 114 and a bottom end 116 that are made of a biocompatible material, such as a TEFLONTM polymer.
- the housing can be fabricated from another material and coated with the biocompatible material.
- a fluid path intended for conveying blood through housing 100 comprises tubing 128 that is wound in a helical or cylindrical coiled shape.
- Tubing 128 is preferably a transparent (or at least translucent) material of the type that can be used for blood vessel reconstruction, such as expanded reinforced polytetrafluoroethylene (ePTFE). Also, optically transparent materials, such as polyvinyl chloride, polyurethane, and TEFLONTM, can be employed for tubing 128.
- ePTFE expanded reinforced polytetrafluoroethylene
- optically transparent materials such as polyvinyl chloride, polyurethane, and TEFLONTM, can be employed for tubing 128.
- Tubing 128 is disposed within housing 100 and has an inlet 104 and an outlet 102, both of which are disposed outside the housing.
- inlet 104 is disposed where tubing 128 passes through an inlet aperture 124 formed within housing 100, adjacent one end, and outlet 102 is disposed where the tubing passes through an outlet aperture 126, adjacent the opposite end of the housing.
- the diameters of inlet 104 and outlet 102 are preferably about 10 millimeters or less so that they are adaptable for grafting to the ends of a severed artery, such as the internal thoracic artery, as discussed below. Further, the diameters of inlet 104 and outlet 102 can be dissimilar to affect the velocity of the blood flow through housing 100.
- a light bar 108 comprising LEDs 110 (or any of the other types of light sources noted above) and a lead 112 is disposed along a center axis of tubing 128 to provide the light that irradiates the blood flowing through the housing.
- An end of the light bar (or at least lead 112) passes through an aperture 118, which is axially disposed in the center of end 116 of the housing.
- Tubing 128 is adapted for coupling to a patient's circulatory system by the use of standard vascular anastomic techniques.
- a suitable artery having a diameter approximately equal to that of inlet 104 and outlet 102 is transected to permit the reactor to be placed in series with the two ends of the artery, so that the blood flowing through the artery flows through the reactor and is exposed to the light emitted by the light source contained therein.
- the proximal ends of inlet 104 and outlet 102 preferably have a smooth profile to facilitate fitting and grafting them to the ends of the transected artery.
- housing 100 After coupling tubing 128 to the artery, blood is circulated from the artery into the proximal end of inlet 104, passes through housing 100 within tubing 128, out of outlet 102, and back into the artery.
- LEDs l lO are energized by an electrical current conveyed through lead 112 and emit light that irradiates the blood circulating through tubing 128.
- an interior surface 122 of housing 100 is preferably coated or lined with a reflective material such as mirrored or white MYLARTM, or any other suitable specular coating to improve the reflection of light towards the blood flowing through tubing 128.
- housing 100 is shown from a top view, and the compactness of its cylindrical shape is clearly evident.
- the compact nature of housing 100 is important when it is disposed at particular sites within a patient's body having limited space for the placement of a medical device.
- FIGURES 3 through 7 Several embodiments of the present invention are illustrated in FIGURES 3 through 7. These embodiments share generally similar housings 200 and 300 having an inlet 202 and an outlet 204 projecting from the center of opposite ends of the housing in regard to the embodiment shown in FIGURES 3, 4, and 5, and an inlet 302 and an outlet 304 projecting from offset points at opposite ends of a housing 300 for the embodiment shown in FIGURE 6.
- Housing 200 comprises a pair of sections 214 that are hermetically fastened together around inlet 202 and outlet 204 and around a lead 208.
- housing 300 also comprises sections that fit together and seal around inlet 302, outlet 304, and a lead 324.
- one of the two sections 214 has an outer ridge 226 that circumscribes the periphery of an interior generally planar surface 224, which is coated or lined with a reflective material such as mirrored or white Mylar.
- An inlet groove 218 and an outlet groove 220 accommodate, respectively, inlet 202 and outlet 204.
- a concave groove 222 in outer ridge 226 accommodates lead 208.
- an array of spaced-apart LEDs 212 mounted on a rectangular substrate or plate 210. In this embodiment, the LEDs are the light source inside housing 200. Plate 210 is slightly smaller in size than section 214 and fits within the inside perimeter of outer ridge 226 when it is disposed adjacent to interior surface 224.
- tubing 216 preferably comprises any of the materials identified above for tubing 128.
- FIGURE 4 a cross-sectional view of housing 200 is illustrated.
- Tubing 216 is shown disposed between a pair of plates 210 that are further disposed between a pair of substantially rectangular sections 214 which are held in close association to form housing 200.
- housing 200 is similarly adaptable for coupling to a patient's circulatory system by the use of standard vascular anastomic techniques.
- the blood enters the proximal end of inlet 202 and passes through serpentine tubing 216, where it is exposed to light irradiation by LED plates 210. Once irradiated, the blood exits tubing 216 through outlet 204 and re-enters the circulatory system of the patient.
- FIGURE 6 An alternative embodiment providing a different fluid path for blood through housing 300 is illustrated in FIGURE 6.
- a molded header manifold 306a is coupled to inlet 302, and a similar molded header manifold 306b is coupled to outlet 304.
- a plurality of parallel cross tubes 308 extend between header manifolds 306a and 306b.
- the header manifolds and cross tubes are made of a transparent or translucent material of the type that is commonly used for blood vessel reconstruction, such as ePTFE. Also, optically transparent materials such as polyvinyl chloride, polyurethane, and TEFLONTM can be employed to construct header manifolds 306a and 306b, and cross tubes 308.
- Housing 300 is constructed in a substantially similar manner as housing 200.
- Housing 300 is formed from a pair of mating rectangular sections 310, each section having a concave shaped inlet groove 312, a concave shaped outlet groove 314, a lead slot 316, and an interior surface 318 that is coated or lined with a reflective material, such as mirrored or white MYLARTM.
- a reflective material such as mirrored or white MYLARTM.
- LEDs 212 are the light source inside housing 300.
- Sections 310 preferably comprise a biocompatible material such as a TEFLONTM polymer or are coated with such a material.
- inlet 302 and outlet 304 are adapted for coupling to a patient's circulatory system by the use of standard vascular anastomic techniques.
- the patient's blood enters the proximal end of inlet 302 and passes through header manifold 306a into a plurality of parallel cross tubes 308, where the blood is exposed to light produced by LEDs 212. After the light-irradiated blood has passed through cross tubes 308, the blood enters header manifold 306b and leaves housing 300 through outlet 304 to re-enter the circulatory system of the patient.
- FIGURES 8 and 9 Yet another alternative embodiment is illustrated in FIGURES 8 and 9.
- This embodiment includes a housing 400, which is generally disk shaped and comprises a top section 414 that is affixed to a similarly shaped bottom section 412. Between top section 414 and bottom section 412 is disposed a coil of tubing 406, which is wound in a substantially planar spiral.
- Tubing 406 is made of the same materials identified for tubing in the embodiments discussed above. Extending downwardly through bottom section 412 from an inner end of the spiraled tubing is an inlet 402; an outlet 404 extends radially outwardly through housing 400 from the outer end of the spiral.
- Generally round plates 408 and 424 are respectively mounted inside bottom section 412 and top section 414, so that an array of spaced-apart LEDs (not separately shown), which are mounted thereon, are disposed adjacent opposite sides of tubing 406.
- the LEDs are energized with an electrical current conveyed through a lead 410 from a suitable internal (or external power source (not shown).
- Plate 408 is slightly smaller in size than bottom section 412 and fits within the inside perimeter of a bottom outside lip 420, against an interior surface 418.
- plate 424 is slightly smaller in size than top section 414 and fits within the inside perimeter of a top outside lip 426.
- a top outer surface 435 and a bottom outer surface 436 of housing 400 are preferably composed of a biocompatible material such as a TEFLONTM polymer. Also, a top interior surface 428 and bottom interior surface 418 are coated or lined with a reflective material such as mirrored or white MYLARTM to improve the reflection of light towards the blood flowing through tubing 406.
- Tubing 406 passes through a round inlet aperture 430, which is disposed in the center of bottom section 412. Further, tubing 406, by passing through an aperture comprising a concave groove 434 formed in top section 414, and a concave groove 432 that is formed in bottom section 412. Also, lead 410 enters housing 400 through an aperture comprising a slot 422 and a slot 416, which are respectively formed in the top and bottom sections. As discussed above in connection with the other embodiments, inlet 402 and outlet 404 are adapted for coupling to a patient's circulatory system by the use of standard vascular anastomic techniques.
- the patient's blood enters the proximal end of tubing 406 through inlet 402 and passes through tubing 406 within housing 400, where the blood is exposed to light emitted by the light sources mounted on plates 408 and 424. After the light irradiated blood has passed through tubing 406, the blood exits housing 400 through outlet 404 and re-enters the circulatory system of the patient.
- FIGURES 10 and 11 Yet another embodiment of the present invention is illustrated in FIGURES 10 and 11.
- a housing 600 is coupled to an external light source 504 through a bundle 500 of optical fibers 506.
- Bundle 500 is divided into planar arrays 604 and 608, each of which includes optical fibers 506 that enter housing 600 along one side of either a top section 606 or a bottom section 602, at spaced-apart points. Ends of optical fibers 506 comprising planar array 604 are terminated along one edge of a top mat 508. Similarly, ends of optical fibers 506 comprising planar array 608 are terminated along one edge of a bottom mat 510. Thus, light conveyed through the optical fibers passes through the ends of the optical fibers and is diffused through the top and bottom mats.
- the light conveyed through the top and bottom mats irradiates blood flowing through a path within housing 600.
- Tubing 216 having a serpentine shape, is shown within housing 600 in the Figures; however, the optical fibers can be used to convey light that irradiates blood flowing through any of the other configurations for a fluid path through any of the reactors that are discussed above.
- the tubing conveying blood is disposed between top mat 508 and bottom mat 510, respectively within top section 606 and bottom section 602. Since top mat 508 and bottom mat 510 convey light received from optical fibers 506, which is produced by external light source 504, the top and bottom mats have a much lower operating temperature than a light source that is included inside any of the housings discussed above. Additionally, a top interior surface 612 and a bottom interior surface 610 are coated or lined with a reflective material such as white or mirrored MYLARTM to enhance the delivery of light to the blood flowing through the reactor. Also, a top outside surface 616 and a bottom outside surface 614 are typically fabricated of or coated with a biocompatible material such as TEFLONTM.
- a particularly suitable site is within the thoracic cavity, adjacent to the sternum. This site provides access to the internal thoracic artery, which can readily be transected to enable the reactor to be attached in series with the transected ends of the artery, without significant adverse effects on the patient.
- the left third true rib is removed and costal cartilage 718 is trimmed to accommodate the positioning of a housing 700 within the resulting cavity.
- Housing 700 is intended to be merely representative of the housings of any of the embodiments discussed above.
- An inlet 714 and an outlet 716 which are also representative of the inlet and outlet for any of the embodiments discussed above, extend from the housing and are attached to the ends of severed internal thoracic artery 726 at a top suture line 724 and a bottom suture line 722, so that blood flowing through the internal thoracic artery is shunted through housing 700.
- housing 700 is tied into the patient's circulatory system and securely positioned as described below, PDT can be administered to the blood flowing through the reactor on either a continuous or intermittent basis, simply by energizing the light source(s).
- housing 700 has tabs disposed on three of its four edges.
- a top tab 704 is disposed on the top edge of housing 700 and has an aperture 706 through which a suture 708 is threaded.
- a costal cartilage 710 for the left second true rib is perforated to form a suture aperture 712 through which suture 708 is looped and tied to secure housing 700.
- This attachment procedure is optionally repeated for a bottom tab 702 that is disposed on the bottom edge of housing 700.
- Bottom tab 702 has an aperture 740 through which a suture 728 is threaded.
- a costal cartilage 730 for the left fourth true rib is perforated to form a suture aperture 732 through which suture 728 is looped and tied to securely position housing 700.
- the attachment of a side tab 734 to a patient's body is accomplished in a similar manner.
- Side tab 734 has an aperture 736 through which a suture 738 is threaded.
- Trimmed costal cartilage 718 is perforated to form a suture aperture 720 through which suture 738 is looped and tied to securely position housing 700 within the patient's body.
- Power supply 800 is preferably an intracorporeal device that is disposed in situ near the reactor, however, it may also be located external to the patient's body. Further, the power supply can be disposed within the housing to provide the electrical current necessary to energize the light sources. In any case, the power supply can comprise a rechargeable battery and/or be inductively coupled to an external source that electromagnetically supplies power to the internal power supply.
- electroluminescent panels can be used as the source of light that irradiates blood flowing through any of the reactor housings. These panels would be disposed on opposite sides of the path along which blood flows through the housing.
- the light sources described in the various embodiments above irradiate the patient's blood from a location inside the reactor housing.
- the light sources can be coupled to the exterior surface of the reactor so that the blood flowing through a fluid within the housing irradiated with light from the sources that passes through a transparent (or at least translucent) housing.
- An externally positioned light source could also have a backing that is coated or lined with a reflective material such as white or mirrored MYLARTM to enhance the deliver)' of light to the blood flowing through the reactor.
- Another aspect of the present invention is directed to reducing skin photosensitivity that can occur as a result of intravenous drug delivery of the photosensitizer.
- the photosensitizer may be administered intra-arterially using a drug pump that injects the photosensitizer into the patient's circulatory system at a point that is just proximal to the site of the reactor.
- the drug should be mostly photobleached by the light administered in the housing before the drug exits the reactor.
- a reservoir of the photosensitizer drug could also be coupled by a tube to the inlet of the reactor and allowed to elute into the blood flow via a porous tip.
- An inherent advantage of the present invention is that excessive heat buildup from the light source is prevented by the continual flow of blood through the housing.
- the total length of the fluid path through the housing extends the circulation time of the patient's blood within the reactor and thus prolongs the duration of the PDT.
- the proper selection and targeting of photosensitizer drugs may cause selective binding to occur to the pathogen and avoid photodynamic injury to normal blood constituents.
- an added benefit is that the photodynamic action on the inner wall of the fluid path through the reactor housing may prevent intimal hyperplasia, which could lead to failure of the graft of a blood vessel to the inlet or outlet of the reactor.
- the inner walls of the fluid path through which blood flows through the reactor may be lined with an anti-coagulant, such as heparin, so as to prevent the clotting of blood cells in the housing.
- an anti-coagulant such as heparin
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97938521A EP1009482A4 (en) | 1996-10-03 | 1997-08-21 | Intracorporeal light treatment of blood |
CA002265507A CA2265507C (en) | 1996-10-03 | 1997-08-21 | Intracorporeal light treatment of blood |
AU40827/97A AU725077B2 (en) | 1996-10-03 | 1997-08-21 | Intracorporeal light treatment of blood |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/725,578 US5702432A (en) | 1996-10-03 | 1996-10-03 | Intracorporeal light treatment of blood |
US08/725,578 | 1996-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998014243A1 true WO1998014243A1 (en) | 1998-04-09 |
Family
ID=24915119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/014781 WO1998014243A1 (en) | 1996-10-03 | 1997-08-21 | Intracorporeal light treatment of blood |
Country Status (6)
Country | Link |
---|---|
US (1) | US5702432A (en) |
EP (1) | EP1009482A4 (en) |
JP (1) | JP3164827B2 (en) |
AU (1) | AU725077B2 (en) |
CA (1) | CA2265507C (en) |
WO (1) | WO1998014243A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6454789B1 (en) | 1999-01-15 | 2002-09-24 | Light Science Corporation | Patient portable device for photodynamic therapy |
US6602274B1 (en) | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
USRE43274E1 (en) | 2002-06-27 | 2012-03-27 | Health Research, Inc. | Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy |
US8192385B2 (en) | 2009-02-25 | 2012-06-05 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US8694092B2 (en) | 2006-04-12 | 2014-04-08 | The Invention Science Fund I, Llc | Lumen-traveling biological interface device and method of use |
US8936629B2 (en) | 2006-04-12 | 2015-01-20 | Invention Science Fund I Llc | Autofluorescent imaging and target ablation |
US9011329B2 (en) | 2004-04-19 | 2015-04-21 | Searete Llc | Lumenally-active device |
US9173837B2 (en) | 2004-04-19 | 2015-11-03 | The Invention Science Fund I, Llc | Controllable release nasal system |
US9198563B2 (en) | 2006-04-12 | 2015-12-01 | The Invention Science Fund I, Llc | Temporal control of a lumen traveling device in a body tube tree |
US9801527B2 (en) | 2004-04-19 | 2017-10-31 | Gearbox, Llc | Lumen-traveling biological interface device |
CN108778357A (en) * | 2016-03-23 | 2018-11-09 | 泰尔茂株式会社 | Light irradiation device |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022479A (en) * | 1998-07-22 | 2000-02-08 | Smirnov; Igor | Method and device for producing activated liquids and methods of use thereof |
JP2002534218A (en) | 1999-01-15 | 2002-10-15 | ライト サイエンシーズ コーポレイション | Non-invasive vascular therapy |
US6273904B1 (en) * | 1999-03-02 | 2001-08-14 | Light Sciences Corporation | Polymer battery for internal light device |
EP1267935A2 (en) | 2000-01-12 | 2003-01-02 | Light Sciences Corporation | Novel treatment for eye disease |
GB2370992B (en) * | 2000-03-23 | 2002-11-20 | Photo Therapeutics Ltd | Therapeutic light source and method |
US7381976B2 (en) | 2001-03-13 | 2008-06-03 | Triton Thalassic Technologies, Inc. | Monochromatic fluid treatment systems |
WO2003020103A2 (en) * | 2001-09-04 | 2003-03-13 | Amit Technology Science & Medicine Ltd. | Method of and device for therapeutic illumination of internal organs and tissues |
US6894456B2 (en) | 2001-11-07 | 2005-05-17 | Quallion Llc | Implantable medical power module |
US20030105409A1 (en) | 2001-11-14 | 2003-06-05 | Donoghue John Philip | Neurological signal decoding |
US7003356B2 (en) * | 2002-03-08 | 2006-02-21 | Quallion Llc | Battery terminal sealing and supporting device and method |
EP1513584A2 (en) * | 2002-06-04 | 2005-03-16 | Cyberkinetics, Inc. | Optically-connected implants and related systems and methods of use |
US7212851B2 (en) * | 2002-10-24 | 2007-05-01 | Brown University Research Foundation | Microstructured arrays for cortex interaction and related methods of manufacture and use |
US8602774B2 (en) * | 2002-12-04 | 2013-12-10 | Bryan Wasylucha | Process of tooth whitening and apparatus therefor |
US7645137B2 (en) * | 2002-12-04 | 2010-01-12 | Bryan Wasyluch | Method and apparatus for bleaching teeth |
CA2465051C (en) * | 2003-04-23 | 2014-11-18 | John Tulip | Switched photodynamic apparatus |
US20050113744A1 (en) * | 2003-11-21 | 2005-05-26 | Cyberkinetics, Inc. | Agent delivery systems and related methods under control of biological electrical signals |
US7553326B2 (en) * | 2003-11-24 | 2009-06-30 | Sweet Richard M | Method and apparatus for preventing dialysis graft intimal hyperplasia |
US7751877B2 (en) * | 2003-11-25 | 2010-07-06 | Braingate Co., Llc | Neural interface system with embedded id |
US7647097B2 (en) | 2003-12-29 | 2010-01-12 | Braingate Co., Llc | Transcutaneous implant |
US8092549B2 (en) | 2004-09-24 | 2012-01-10 | The Invention Science Fund I, Llc | Ciliated stent-like-system |
US7998060B2 (en) | 2004-04-19 | 2011-08-16 | The Invention Science Fund I, Llc | Lumen-traveling delivery device |
US8361013B2 (en) | 2004-04-19 | 2013-01-29 | The Invention Science Fund I, Llc | Telescoping perfusion management system |
US7850676B2 (en) | 2004-04-19 | 2010-12-14 | The Invention Science Fund I, Llc | System with a reservoir for perfusion management |
US8337482B2 (en) | 2004-04-19 | 2012-12-25 | The Invention Science Fund I, Llc | System for perfusion management |
US7857767B2 (en) | 2004-04-19 | 2010-12-28 | Invention Science Fund I, Llc | Lumen-traveling device |
US8560041B2 (en) | 2004-10-04 | 2013-10-15 | Braingate Co., Llc | Biological interface system |
US20060183987A1 (en) * | 2004-12-20 | 2006-08-17 | Murray John K | Intravenous ultraviolet implant |
US20070032738A1 (en) | 2005-01-06 | 2007-02-08 | Flaherty J C | Adaptive patient training routine for biological interface system |
US8095209B2 (en) | 2005-01-06 | 2012-01-10 | Braingate Co., Llc | Biological interface system with gated control signal |
US20060206167A1 (en) | 2005-01-06 | 2006-09-14 | Flaherty J C | Multi-device patient ambulation system |
US8812096B2 (en) | 2005-01-10 | 2014-08-19 | Braingate Co., Llc | Biological interface system with patient training apparatus |
US8060194B2 (en) | 2005-01-18 | 2011-11-15 | Braingate Co., Llc | Biological interface system with automated configuration |
US8386186B2 (en) * | 2005-07-21 | 2013-02-26 | The Invention Science Fund I, Llc | Selective resonance of chemical structures |
US8112233B2 (en) * | 2005-07-21 | 2012-02-07 | The Invention Science Fund I, Llc | Selective resonance of chemical structures |
US9427465B2 (en) | 2005-07-21 | 2016-08-30 | Deep Science, Llc | Selective resonance of chemical structures |
US20070021924A1 (en) * | 2005-07-21 | 2007-01-25 | Ishikawa Muriel Y | Selective resonance of chemical structures |
US8364412B2 (en) * | 2005-07-21 | 2013-01-29 | The Invention Science Fund I, Llc | Selective resonance of chemical structures |
US8195403B2 (en) * | 2005-07-21 | 2012-06-05 | The Invention Science Fund I, Llc | Selective resonance of bodily agents |
US8346484B2 (en) | 2005-07-21 | 2013-01-01 | The Invention Science Fund I, Llc | Selective resonance of chemical structures |
US8386183B2 (en) * | 2005-07-21 | 2013-02-26 | The Invention Science Fund I, Llc | Selective resonant reconfiguration of chemical structures |
US9211332B2 (en) | 2005-07-21 | 2015-12-15 | The Invention Science Fund I, Llc | Selective resonance of bodily agents |
US20100023021A1 (en) * | 2005-12-27 | 2010-01-28 | Flaherty J Christopher | Biological Interface and Insertion |
US8163003B2 (en) | 2006-06-16 | 2012-04-24 | The Invention Science Fund I, Llc | Active blood vessel sleeve methods and systems |
US8165663B2 (en) | 2007-10-03 | 2012-04-24 | The Invention Science Fund I, Llc | Vasculature and lymphatic system imaging and ablation |
US8285367B2 (en) | 2007-10-05 | 2012-10-09 | The Invention Science Fund I, Llc | Vasculature and lymphatic system imaging and ablation associated with a reservoir |
US8285366B2 (en) | 2007-10-04 | 2012-10-09 | The Invention Science Fund I, Llc | Vasculature and lymphatic system imaging and ablation associated with a local bypass |
US20090192493A1 (en) * | 2008-01-03 | 2009-07-30 | University Of Southern California | Implantable drug-delivery devices, and apparatus and methods for refilling the devices |
US8246565B2 (en) * | 2009-02-25 | 2012-08-21 | The Invention Science Fund I, Llc | Device for passively removing a target component from blood or lymph of a vertebrate subject |
US8317737B2 (en) | 2009-02-25 | 2012-11-27 | The Invention Science Fund I, Llc | Device for actively removing a target component from blood or lymph of a vertebrate subject |
US10894173B2 (en) | 2012-04-05 | 2021-01-19 | Light Line Medical, Inc. | Methods and apparatus to deliver therapeutic, non-ultraviolet electromagnetic radiation to inactivate infectious agents and/or to enhance healthy cell growth via a catheter residing in a body cavity |
US11229808B2 (en) | 2012-04-05 | 2022-01-25 | Light Line Medical, Inc. | Methods and apparatus to deliver therapeutic, non-ultraviolet electromagnetic radiation versatilely via a catheter residing in a body cavity |
US10307612B2 (en) | 2012-04-05 | 2019-06-04 | Light Line Medical, Inc. | Methods and apparatus to deliver therapeutic, non-ultraviolet electromagnetic radiation to inactivate infectious agents and/or to enhance healthy cell growth via a catheter residing in a body cavity |
US9808647B2 (en) | 2012-04-05 | 2017-11-07 | Veritas Medical, L.L.C. | Methods and apparatus to inactivate infectious agents on a catheter residing in a body cavity |
US11497932B2 (en) | 2012-04-05 | 2022-11-15 | Light Line Medical, Inc. | Electromagnetic radiation delivery and monitoring system and methods for preventing, reducing and/or eliminating catheter-related infections during institutional or in-home use |
US11229728B1 (en) | 2020-08-24 | 2022-01-25 | Light Line Medical, Inc. | Method and apparatus to deliver therapeutic, non-ultraviolet electromagnetic radiation in a dialysis system |
GB2525109B8 (en) | 2013-02-07 | 2019-08-07 | Rocomp Global Llc | Electromagnetic radiation targeting devices, assemblies, systems and methods |
US9208296B1 (en) | 2014-06-19 | 2015-12-08 | Norman Romanick | Prevention of use of a contaminated medical product |
KR102342227B1 (en) * | 2014-12-02 | 2021-12-24 | 쑤저우 레킨 세미컨덕터 컴퍼니 리미티드 | Optical apparatus |
FR3031041B1 (en) * | 2014-12-26 | 2020-11-06 | Commissariat Energie Atomique | IMPLANTABLE OPTICAL BRAIN STIMULATION DEVICE INCLUDING A MULTI-CHANNEL CATHETER |
US20170021042A1 (en) * | 2015-07-23 | 2017-01-26 | Terumo Bct Biotechnologies, Llc | Flow-Through Pathogen Reduction |
DE102015114404A1 (en) * | 2015-08-28 | 2017-03-02 | Nephro-Solutions Ag | immunomodulation |
US11672898B2 (en) | 2018-06-08 | 2023-06-13 | Oregon State University | Microfluidic removal of excess bilirubin from blood |
WO2020023942A2 (en) | 2018-07-27 | 2020-01-30 | Terumo Bct Biotechnologies, Llc | Fluid flow-through |
EP4127126A1 (en) * | 2020-03-24 | 2023-02-08 | Colorado State University Research Foundation | Photo reactor devices, systems, and methods of use thereof |
KR102546057B1 (en) * | 2021-06-17 | 2023-06-22 | 주식회사 아이엘사이언스 | Condensation improvement lighting fixtures |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5263925A (en) * | 1991-07-22 | 1993-11-23 | Gilmore Jr Thomas F | Photopheresis blood treatment |
US5445608A (en) | 1993-08-16 | 1995-08-29 | James C. Chen | Method and apparatus for providing light-activated therapy |
US5501662A (en) * | 1992-05-22 | 1996-03-26 | Genetronics, Inc. | Implantable electroporation method and apparatus for drug and gene delivery |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4613322A (en) * | 1982-12-08 | 1986-09-23 | Edelson Richard Leslie | Method and system for externally treating the blood |
US4915683A (en) * | 1986-11-21 | 1990-04-10 | The Medical College Of Wisconsin, Inc. | Antiviral method, agents and apparatus |
US4878891A (en) * | 1987-06-25 | 1989-11-07 | Baylor Research Foundation | Method for eradicating infectious biological contaminants in body tissues |
WO1992011060A1 (en) * | 1990-12-20 | 1992-07-09 | Baxter International Inc. | Systems for eradicating contaminants in fluids |
EP0516836B1 (en) * | 1990-12-20 | 1996-03-13 | Baxter International Inc. | A device and method for eradicating contaminants in fluids |
US5261874A (en) * | 1991-09-16 | 1993-11-16 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Extra-corporeal blood access, sensing, and radiation methods and apparatuses |
US5354774A (en) * | 1992-12-24 | 1994-10-11 | Yale University | Inhibition of smooth muscle cell proliferation by 8-methoxypsoralen photoactivated by visible light |
US5527704A (en) * | 1994-12-06 | 1996-06-18 | Baxter International Inc. | Apparatus and method for inactivating viral contaminants in body fluids |
-
1996
- 1996-10-03 US US08/725,578 patent/US5702432A/en not_active Expired - Fee Related
-
1997
- 1997-08-21 EP EP97938521A patent/EP1009482A4/en not_active Withdrawn
- 1997-08-21 JP JP51652898A patent/JP3164827B2/en not_active Expired - Fee Related
- 1997-08-21 WO PCT/US1997/014781 patent/WO1998014243A1/en not_active Application Discontinuation
- 1997-08-21 AU AU40827/97A patent/AU725077B2/en not_active Ceased
- 1997-08-21 CA CA002265507A patent/CA2265507C/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5263925A (en) * | 1991-07-22 | 1993-11-23 | Gilmore Jr Thomas F | Photopheresis blood treatment |
US5501662A (en) * | 1992-05-22 | 1996-03-26 | Genetronics, Inc. | Implantable electroporation method and apparatus for drug and gene delivery |
US5445608A (en) | 1993-08-16 | 1995-08-29 | James C. Chen | Method and apparatus for providing light-activated therapy |
Non-Patent Citations (1)
Title |
---|
See also references of EP1009482A4 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6602274B1 (en) | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
US6454789B1 (en) | 1999-01-15 | 2002-09-24 | Light Science Corporation | Patient portable device for photodynamic therapy |
US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
USRE43274E1 (en) | 2002-06-27 | 2012-03-27 | Health Research, Inc. | Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy |
US9011329B2 (en) | 2004-04-19 | 2015-04-21 | Searete Llc | Lumenally-active device |
US9801527B2 (en) | 2004-04-19 | 2017-10-31 | Gearbox, Llc | Lumen-traveling biological interface device |
US9173837B2 (en) | 2004-04-19 | 2015-11-03 | The Invention Science Fund I, Llc | Controllable release nasal system |
US9198563B2 (en) | 2006-04-12 | 2015-12-01 | The Invention Science Fund I, Llc | Temporal control of a lumen traveling device in a body tube tree |
US8694092B2 (en) | 2006-04-12 | 2014-04-08 | The Invention Science Fund I, Llc | Lumen-traveling biological interface device and method of use |
US8936629B2 (en) | 2006-04-12 | 2015-01-20 | Invention Science Fund I Llc | Autofluorescent imaging and target ablation |
US9220917B2 (en) | 2006-04-12 | 2015-12-29 | The Invention Science Fund I, Llc | Systems for autofluorescent imaging and target ablation |
US9408530B2 (en) | 2006-04-12 | 2016-08-09 | Gearbox, Llc | Parameter-based navigation by a lumen traveling device |
US8454547B2 (en) | 2009-02-25 | 2013-06-04 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US8430831B2 (en) | 2009-02-25 | 2013-04-30 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US8206330B2 (en) | 2009-02-25 | 2012-06-26 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US8192385B2 (en) | 2009-02-25 | 2012-06-05 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
CN108778357A (en) * | 2016-03-23 | 2018-11-09 | 泰尔茂株式会社 | Light irradiation device |
CN108778357B (en) * | 2016-03-23 | 2021-12-03 | 泰尔茂株式会社 | Light irradiation device |
Also Published As
Publication number | Publication date |
---|---|
JP3164827B2 (en) | 2001-05-14 |
US5702432A (en) | 1997-12-30 |
EP1009482A1 (en) | 2000-06-21 |
EP1009482A4 (en) | 2001-01-17 |
AU725077B2 (en) | 2000-10-05 |
CA2265507A1 (en) | 1998-04-09 |
CA2265507C (en) | 2002-02-05 |
JP2000503579A (en) | 2000-03-28 |
AU4082797A (en) | 1998-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5702432A (en) | Intracorporeal light treatment of blood | |
AU748125B2 (en) | Application of light at plural treatment sites within a tumor to increase the efficacy of light therapy | |
AU694868B2 (en) | Microminiature illuminator for administering photodynamic therapy | |
JP7074855B2 (en) | Methods and devices for delivering therapeutic non-UV electromagnetic radiation via catheters present in body cavities to inactivate infectious pathogens and / or promote normal cell growth. | |
US5445608A (en) | Method and apparatus for providing light-activated therapy | |
CA2199384C (en) | Phototherapeutic apparatus | |
US20040073278A1 (en) | Method of and device for therapeutic illumination of internal organs and tissues | |
US20020087206A1 (en) | Implantable intracranial photo applicator for long term fractionated photodynamic and radiation therapy in the brain and method of using the same | |
US10894173B2 (en) | Methods and apparatus to deliver therapeutic, non-ultraviolet electromagnetic radiation to inactivate infectious agents and/or to enhance healthy cell growth via a catheter residing in a body cavity | |
US11229728B1 (en) | Method and apparatus to deliver therapeutic, non-ultraviolet electromagnetic radiation in a dialysis system | |
US20220161046A1 (en) | Catheter and light irradiation system | |
JP3246227U (en) | Method and apparatus for variably delivering therapeutic non-ultraviolet electromagnetic radiation via a catheter placed within a body cavity | |
EP1527798A2 (en) | Diffusive tip assembly | |
KR20220058307A (en) | Catheter inner tube for transferring light energy | |
CA2291958A1 (en) | Phototherapy apparatus and method for hyperbilirubinemia treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2265507 Country of ref document: CA Ref country code: CA Ref document number: 2265507 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997938521 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997938521 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997938521 Country of ref document: EP |